{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:02:49Z","timestamp":1789401769803,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108333","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:17:57Z","timestamp":1783178277000},"page":"108333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles"],"prefix":"10.1016","volume":"231","author":[{"given":"Yao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adili","family":"Tuersun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subinuer","family":"Abuduaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7088-8728","authenticated-orcid":false,"given":"Huanxue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2026.108333_bib1","first-page":"303","article-title":"Metabolic syndrome in obese adolescents: a comparison of three different diagnostic criteria","volume":"88","author":"Costa","year":"2012","journal-title":"J. Pediatr."},{"issue":"_1","key":"10.1016\/j.phrs.2026.108333_bib2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/advances\/nmy055","article-title":"Humans against obesity: who will win?","volume":"10","author":"Caballero","year":"2019","journal-title":"Adv. Nutr."},{"issue":"1","key":"10.1016\/j.phrs.2026.108333_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol. Rev."},{"issue":"14","key":"10.1016\/j.phrs.2026.108333_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa1713231","article-title":"Change in overweight from childhood to early adulthood and risk of type 2 diabetes","volume":"378","author":"Bjerregaard","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108333_bib5","first-page":"768","article-title":"Current insights and emerging trends in early-onset type 2 diabetes. The lancet","volume":"11","author":"Misra","year":"2023","journal-title":"Diabetes & Endocrinol."},{"issue":"20","key":"10.1016\/j.phrs.2026.108333_bib6","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1056\/NEJMoa1010112","article-title":"Childhood adiposity, adult adiposity, and cardiovascular risk factors","volume":"365","author":"Juonala","year":"2011","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108333_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108333_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13052-022-01205-w","article-title":"The adolescent with obesity: what perspectives for treatment?","volume":"48","author":"Nicolucci","year":"2022","journal-title":"Ital. J. Pediatr."},{"issue":"2","key":"10.1016\/j.phrs.2026.108333_bib9","article-title":"Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.phrs.2026.108333_bib10","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3150","article-title":"Unique Needs of the Adolescent","volume":"144","author":"Alderman","year":"2019","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.phrs.2026.108333_bib11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/oby.23395","article-title":"Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial","volume":"30","author":"Fox","year":"2022","journal-title":"Obes. (Silver Spring Md. )"},{"issue":"22","key":"10.1016\/j.phrs.2026.108333_bib12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108333_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgac549","article-title":"Liraglutide for Weight Management in Children and Adolescents with Prader-Willi Syndrome and Obesity","volume":"108","author":"Diene","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108333_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamapediatrics.2013.1045","article-title":"The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial","volume":"167","author":"Kelly","year":"2013","journal-title":"JAMA Pediatr."},{"issue":"2","key":"10.1016\/j.phrs.2026.108333_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001706","article-title":"Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events","volume":"8","author":"Lingvay","year":"2020","journal-title":"BMJ Open. Diabetes Res. & care"},{"issue":"8","key":"10.1016\/j.phrs.2026.108333_bib16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1007\/s00125-020-05174-9","article-title":"Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials","volume":"63","author":"Sargeant","year":"2020","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.phrs.2026.108333_bib17","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamapediatrics.2025.3243","article-title":"Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"179","author":"Kotecha","year":"2025","journal-title":"JAMA Pediatr."},{"issue":"8","key":"10.1016\/j.phrs.2026.108333_bib18","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/s41366-025-01790-w","article-title":"Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis","volume":"49","author":"Sedenho-Prado","year":"2025","journal-title":"Int. J. Obes. (2005)"},{"issue":"6","key":"10.1016\/j.phrs.2026.108333_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13177","article-title":"GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis","volume":"22","author":"Chadda","year":"2021","journal-title":"Obes. Rev. Off. J. Int. Assoc. Study Obes."},{"key":"10.1016\/j.phrs.2026.108333_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpeds.2021.05.009","article-title":"Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis","volume":"236","author":"Ryan","year":"2021","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.phrs.2026.108333_bib21","first-page":"323","article-title":"Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight\/Obese and\/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials","volume":"16","author":"Dai","year":"2024","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108333_bib22","article-title":"Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"10","author":"Cornejo-Estrada","year":"2023","journal-title":"Child. (Basel Switz. )"},{"key":"10.1016\/j.phrs.2026.108333_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.897776","article-title":"Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108333_bib24","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1111\/dom.15777","article-title":"Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis","volume":"26","author":"Shamim","year":"2024","journal-title":"J. ]. Diabetes Obes. & Metab."},{"issue":"7","key":"10.1016\/j.phrs.2026.108333_bib25","article-title":"Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis","volume":"17","author":"Liu","year":"2024","journal-title":"Pharm. (Basel Switz. )"},{"key":"10.1016\/j.phrs.2026.108333_bib26","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin. Res. Ed. )"},{"key":"10.1016\/j.phrs.2026.108333_bib27","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clin. Res. Ed. )"},{"issue":"4","key":"10.1016\/j.phrs.2026.108333_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS. Med."},{"key":"10.1016\/j.phrs.2026.108333_bib29","unstructured":"Higgins J.P.T., T J., Chandler J., et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). \u3008www.training.cochrane.org\/handbook\u3009."},{"issue":"32","key":"10.1016\/j.phrs.2026.108333_bib30","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ Can. Med. Assoc. J. = J. De. l\u2032Assoc. Med. Can."},{"issue":"6","key":"10.1016\/j.phrs.2026.108333_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2026.108333_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metab. Clin. Exp."},{"issue":"19","key":"10.1016\/j.phrs.2026.108333_bib33","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2146\/ajhp150990","article-title":"Role of glucagon-like peptide 1 receptor agonists in management of obesity","volume":"73","author":"Isaacs","year":"2016","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"issue":"8","key":"10.1016\/j.phrs.2026.108333_bib34","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes care"},{"issue":"12","key":"10.1016\/j.phrs.2026.108333_bib35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108333_bib36","first-page":"391","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"issue":"2","key":"10.1016\/j.phrs.2026.108333_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-5793(94)00699-7","article-title":"Glucagon-like peptide 1: a potent glycogenic hormone","volume":"349","author":"Valverde","year":"1994","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.phrs.2026.108333_bib38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2026.108333_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102355","article-title":"The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms","volume":"69","author":"Ribeiro-Silva","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108333_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49364-x","article-title":"Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats","volume":"9","author":"Katsurada","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108333_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108333_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073050","article-title":"GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.phrs.2026.108333_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.clinthera.2024.06.015","article-title":"Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"46","author":"Tuersun","year":"2024","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108333_bib44","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.phrs.2026.108333_bib45","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2026.108333_bib46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial","volume":"392","author":"Fox","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108333_bib47","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/clinem\/dgad669","article-title":"Glycemia and Gluconeogenesis with Metformin and Liraglutide: a Randomized Trial in Youth-onset Type 2 Diabetes","volume":"109","author":"Dietsche","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2026.108333_bib48","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2337\/dc21-2275","article-title":"Once-Weekly Exenatide in Youth With Type 2 Diabetes","volume":"45","author":"Tamborlane","year":"2022","journal-title":"Diabetes care"},{"issue":"5","key":"10.1016\/j.phrs.2026.108333_bib49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"New. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.phrs.2026.108333_bib50","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-Weekly Semaglutide in Adolescents with Obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108333_bib51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgac549","article-title":"Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity","volume":"108","author":"Diene","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2026.108333_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12624","article-title":"A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity","volume":"15","author":"Weghuber","year":"2020","journal-title":"Pediatr. Obes."},{"issue":"7","key":"10.1016\/j.phrs.2026.108333_bib53","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in Children and Adolescents with Type 2 Diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"New. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108333_bib54","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/oby.2011.337","article-title":"Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study","volume":"20","author":"Kelly","year":"2012","journal-title":"Obes. (Silver Spring Md. )"},{"issue":"6","key":"10.1016\/j.phrs.2026.108333_bib55","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/pedi.13343","article-title":"A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes","volume":"23","author":"Barrientos-P\u00e9rez","year":"2022","journal-title":"Pediatr. Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2026.108333_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12495","article-title":"Liraglutide effects in a paediatric (7-11 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Mastrandrea","year":"2019","journal-title":"Pediatr. Obes."},{"key":"10.1016\/j.phrs.2026.108333_bib57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years","volume":"181","author":"Danne","year":"2017","journal-title":"J. Pediatr."},{"issue":"10","key":"10.1016\/j.phrs.2026.108333_bib58","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/dia.2013.0366","article-title":"Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Klein","year":"2014","journal-title":"Diabetes Technol. & Ther."},{"issue":"4","key":"10.1016\/j.phrs.2026.108333_bib59","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.clinthera.2009.04.005","article-title":"Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study","volume":"31","author":"Malloy","year":"2009","journal-title":"Clin. Ther."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:05:25Z","timestamp":1789398325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"alternative-id":["S1043661826002483"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108333","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108333"}}